Our future studies will focus on the mechanisms through which these factors influence expression of FXYD3 on human breast cancer cells, and analysis of how such changes in FXYD3 evoked by estrogen or tamoxifen affect proliferative activity of these cells. This evidence concerns the gene FXYD3 and breast carcinoma.